Journal List > J Korean Ophthalmol Soc > v.53(7) > 1009124

TOOLS
Park, Lew, and Song: Intravitreal Clindamycin Injection for Toxoplasmic Retinochoroiditis
Case Report
Journal of the Korean Ophthalmological Society

Journal of the Korean Ophthalmological Society 2012; 53(7): 1046-1052.

Published online: 13 July 2012

DOI: https://doi.org/10.3341/jkos.2012.53.7.1046

Intravitreal Clindamycin Injection for Toxoplasmic Retinochoroiditis

Suyoun Park, MD, Ho Min Lew, MD, Ji Hun Song, MD

Department of Ophthalmology, Ajou University School of Medicine, Suwon, Korea.

Address reprint requests to Ji Hun Song, MD. Department of Ophthalmology, Ajou University Hospital, #164 Worldcup-ro, Yeongtong-gu, Suwon 443-721, Korea. Tel: 82-31-219-5260, Fax: 82-31-219-5259, dreyesong@naver.com

Received 7 June 2011       Accepted 4 May 2012

Copyright © 2012 The Korean Ophthalmological Society

Abstract

Purpose

To present cases of toxoplasmic retinochoroiditis (TRC) treated successfully with intravitreal clindamycin injection.

Case summary

(Case 1) A 41-year-old man presented with blurred left eye vision for several months. The patient had a large chorioretinal scar with infiltrations at the boundaries, and fluorescein angiography (FA) showed active retinochoroiditis. Antitoxoplasmosis (antiTX) immunoglobulin G (IgG) was positive, and the patient was started on antiTX medication. Despite several weeks of treatment with maximum doses of antiTx, the TRC progressed and visual acuity worsened. Pars plana vitrectomy (PPV) with intravitreal clindamycin injection (1.0 mg/0.1 ml) was performed, and an additional injection was given 4 weeks later. Six weeks after the second injection, TRC wascompletely resolved with 20/20 vision. (Case 2) A 67-year-old man presented with decreased left eye vision for 1 year. Fundus examinations showed vitreous opacity and epiretinal membranes. The FA revealed retinochoroiditis and the antiTX IgG titer was elevated. The presumed diagnosis was TRC, and oral medications of trimethoprim-sulfamethoxazole, clindamycin, and prednisolone was administered. Inflammation began to improve however, as the patient was not tolerating systemic antiTx medications, an intravitreal injection of clindamycin (1.0 mg/0.1 ml) was administered with PPV. The patientdiscontinued oral medication after surgery, and the inflammation resolved 5 weeks later.

Conclusions

Intravitreal clindamycin injections may be an additional treatment option for TRC in patients who are unable to tolerate systemic therapy or whose disease progresses despite systemic therapy.

Keywords: Clindamycin, Intravitreal injection, Toxoplasmic retinochoroiditis

Figures and Tables

Figure 1
Case 1. Fundus photograph and fluorescein angiographs of the left eye at initial visit. Fundus photograph shows a huge pigmented scar at the superior retina with multiple infiltrations at its margins. The focal retinochoroiditis at the inferior margin of the main lesion (arrow) threatened the fovea (A). Fluorescein angiography reveals staining of the scar and late leakage at the margins (B, C).
jkos-53-1046-g001
Figure 2
Six weeks after initiation of antitoxoplasmosis medication. Fundus photograph shows that the vitreous opacity was exacerbated and the area of retinochoroiditis had enlarged. A new focal inflammatory lesion(arrow) is noted at the inferior macula (A). In fluorescein angiography, more intense leakage of the lesion is noted with blockage due to increased vitreous opacity. An additional new focal retinitis site (arrowhead) is detected at the temporal macula (B).
jkos-53-1046-g002
Figure 3
Fundus photograph and fluorescein angiographs at 6 weeks after the second intravitreal clindamycin injection. In fundus photograph, vitreous haze due to vitritis is cleared and all the inflammatory lesions have changed to chorioretinal scars (A). Fluorescein angiography reveals that the previous retinochoroiditis lesions are mainly stained without late leakage (B, C).
jkos-53-1046-g003
Figure 4
Case 2. Initial fundus photograph of the left eye shows vitreous opacity and a premacular membrane (A). Fluorescein angiography at presentation reveals lateleakage of retinal vasculatures and diffuse retinochoroidal leakage involving the macula (B).
jkos-53-1046-g004
Figure 5
Fundus photograph at 10 weeks after vitrectomy and intravitreal clindamycin injection. Fundus photograph shows clearing of vitreous opacity and no premacular membrane.
jkos-53-1046-g005

References

1. Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina. 2007. 27:952–957.
2. Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011. 118:134–141.
3. Koo L, Young LH. Management of ocular toxoplasmosis. Int Ophthalmol Clin. 2006. 46:183–193.
4. Kishore K, Conway MD, Peyman GA. Intravitreal clindamycin and dexamethasone for toxoplasmic retinochoroiditis. Ophthalmic Surg Lasers. 2001. 32:183–192.
5. Martinez CE, Zhang D, Conway MD, Peyman GA. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol. 1998-1999. 22:85–88.
6. Lasave AF, Díaz-Llopis M, Muccioli C, et al. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology. 2010. 117:1831–1838.
7. Wong R, dell'Omo R, Marino M, et al. Toxoplasma gondii: an atypical presentation of toxoplasma as optic disc swelling and hemispherical retinal vein occlusion treated with intravitreal clindamycin. Int Ophthalmol. 2009. 29:195–198.
8. Montoya JG, Parmley S, Liesenfeld O, et al. Use of the polymerase chain reaction for diagnosis of ocular toxoplasmosis. Ophthalmology. 1999. 106:1554–1563.
9. Nicholson DH, Wolchok EB. Ocular toxoplasmosis in an adult receiving long-term corticosteroid therapy. Arch Ophthalmol. 1976. 94:248–254.
10. Nozik RA. Results of treatment of ocular toxoplasmosis with injectable corticosteroids. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977. 83:811–818.
11. Bovey EH. Usefulness of vitrectomy in the treatment of ocular toxoplasmosis. Int J Med Sci. 2009. 6:139.
12. Adan A, Giralt J, Alvarez G, et al. Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. Eur J Ophthalmol. 2009. 19:1039–1043.
13. Papadopoulou DN, Petropoulos IK, Mangioris G, et al. Pars plana vitrectomy in the treatment of severe complicated toxoplasmic retinochoroiditis. Eur J Ophthalmol. 2011. 21:83–88.
TOOLS
Similar articles